2002, Número 3
Inhibidores selectivos de la ciclooxigenasa-2: Usos potenciales en perros
Lizárraga MI, Sumano LH, Castillo AF
Idioma: Español/Inglés
Referencias bibliográficas: 81
Paginas: 285-307
Archivo PDF: 147.58 Kb.
RESUMEN
La gran variedad y frecuencia de efectos adversos que producen los antiinflamatorios no esteroidales (AINE) limitan su uso en perros. Estos fármacos, en mayor o menor medida, inhiben a las ciclooxigenasas (COX), de las cuales existen al menos dos isoformas: COX-1 y COX-2. Se cree que la inhibición de la COX-1 ocasiona los efectos adversos de los AINE y que el bloqueo de la COX-2 se relaciona con sus efectos terapéuticos. Hasta cierto punto esta teoría parece ser cierta en humanos que sufren de osteoartritis y reciben inhibidores selectivos de la COX-2. Si esta hipótesis también se cumple en perros, el uso de los inhibidores selectivos de la COX-2 tendría un lugar importante dentro de la terapéutica canina. Este ensayo destaca aspectos relevantes de la fisiopatología de la COX-2 en diversos órganos y sistemas (por ejemplo, tubo gastrointestinal, riñón, sistema nervioso central) y, a partir de esta información, se discuten los posibles usos y efectos adversos de los inhibidores selectivos de la COX-2 (por ejemplo, celecoxib, nimesulida, NS-398) en perros. También se presenta información clínico-farmacológica del uso de inhibidores selectivos de la COX-2 (por ejemplo, carprofeno, nimesulida y celecoxib) derivada específicamente de perros.
REFERENCIAS (EN ESTE ARTÍCULO)
Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
2. Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J Gastroenterol 1998;33:618-624.
3. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
4. Appleton I, Tomlinson A, Willoughby DA. Induction of cyclo-oxygenase and nitric oxide synthase in inflammation. Adv Pharmacol 1996;35:27-78.
5. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase - a review. Prostaglandins Lipid Mediat 1999;56:341-361.
6. Kirchner T, Argentieri DC, Barbone AG, Singer M, Steber M, Ansell J, et al. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipooxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther 1997;282:1094-1101.
7. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995;83:483-492.
8. Mahler JF, Davis BJ, Morham SG, Langenbach R. Disruption of cyclooxygenase genes in mice. Toxicol Pathol 1996;24:717-719.
9. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther 1998;286:1383-1390.
10. Tsukada K, Hasegawa T, Tsutsumi S, Kuwano H. Roles of cyclooxygenase-2 in tissue injury during hemorrhagic shock. Shock 2000;13:392-396.
11. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, van de Putte LBA, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
12. Venturini CM, Isakson P, Needleman P. Non-steroidal anti-inflammatory drug-induced renal failure: a brief review of the role of cyclo-oxygenase isoforms. Curr Opin Nephrol Hypertension 1998;7:79-82.
13. Khan KNM, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
14. Black SC, Brideau C, Cirino M, Belley M, Bosquet J, Chan C, Rodger IW. Differential effect of a selective cyclooxygenase-2 inhibitor versus indomethacin on renal blood flow in conscious volume-depleted dogs. J Cardiovasc Pharmacol 1998;32:686-694.
15. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741.
16. Kaufmann WE, Andersson KI, Isakson PC, Worley PF. Cyclooxygenases and the central nervous system. Prostaglandins 1997;54:601-624.
17. Willingale HL, Gardiner NJ, McLymont N, Giblett S, Grubb BD. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 1997;122:1593-1604.
18. Minghetti L, Nicolini A, Polazzi E, Greco A, Perretti M, Parente L, Levi G. Down regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol 1999;126:1307-1314.
19. Cullen L, Kelly L, Connor SO, Fitzgerald DJ. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther 1998;287:578-582.
20. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.
21. Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol 1999;128:1121-1132.
22. Ermert L, Ermert M, Althoff A, Merkle M, Grimminger F, Seeger W. Vasoregulatory prostanoid generation proceed via cyclooxygenase-2 in noninflammed rat lungs. J Pharmacol Exp Ther 1998;286:1309-1314.
23. Johnson SR, Knox AJ. Synthetic functions of airway smooth muscle in asthma. Trends Pharmacol Sci 1997;18:288-292.
24. Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 2001;110 (Suppl3A):43S-45S.
25. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994;91:12013-12017.
26. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 1998;95:13313-13318.
27. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997;283:1069-1075.
28. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis. J Am Med Assoc 1999;282:1921-1928.
29. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-1105.
30. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-2111.
31. Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999;126:1200-1204.
32. Wallace JL. Selective COX-2 inhibitors: is the water becoming muddy? Trends Pharmacol Sci 1999;20:4-6.
33. Toutain PL, Cester CC, Haak T, Laroute V. A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog. J Vet Pharmacol Ther 2001;24:43-55.
34. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998;59:1441-1446.
35. Osuka K, Suzuki Y, Watanabe Y, Takayasu M, Yoshida J, Busija DW. Inducible cyclooxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage. Stroke 1998;29:1219-1222.
36. Resnick DK, Graham SH, Dixon CE, Marion DW. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 2001;15:1005-1013.
37. Yamamoto T, Nozaki-Taguchi N. Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor. Brain Res 1996;739:104-110.
38. Ehrich EW, Dallob A, de Lepeleire I, van Hecken A, Riendeau D, Yuan W, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65:336-347.
39. Chan CC, Panneton M, Taylor AM, Therien M, Rodger IW. A selective inhibitor of cyclooxygenase-2 reverses endotoxin-induced pyretic responses in non-human primates. Eur J Pharmacol 1997;237:221-225.
40. Parrott RF, Vellucci SV. Comparison of the antipyretic actions of indomethacin and L-745,337, a selective cyclooxygenase-2 inhibitor, in endotoxin-treated prepubertal pigs. Gen Pharmacol 1998;30:65-69.
41. Johnston SA, Budsberg SC. Nonsteroidal anti-inflammatory drugs and corticosteroids for the management of canine osteoarthritis. Vet Clin North Am Small Anim Pract 1997;27:841-862.
42. Khan KNM, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
43. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998;95:681-686.
44. Barnes PJ, Adcock IM. NF-kB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997;18:46-50.
45. Rogers DF, Giembycz MA. Asthma therapy for the 21st century. Trends Pharmacol Sci 1998;19:160-164.
46. Moore JN, Barton MH. An update on endotoxaemia. Part 1: mechanisms and pathways. Equine Vet Educ 1998;10:300-306.
47. Leach M, Hamilton LC, Olbrich A, Wray GM, Thiemermann C. Effects of inhibitors of the activity of cyclo-oxygenase-2 on the hypotension and multiple organ dysfunction caused by endotoxin: a comparison with dexamethasone. Br J Pharmacol 1998;124:586-592.
48. Gust R, Kozlowski JK, Stephenson AH, Schuster DP. Role of cyclooxygenase-2 in oleic acid-induced acute lung injury. Am J Resp Crit Care Med 1999;160:1165-1170.
49. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997;18:30-34.
50. Vasseur PB, Johnson AL, Budsberg SC, Lincoln JD, Toombs JP, et al. Randomized, controlled trial of the efficacy of carprofen, a nonsteroidal anti-inflammatory drug, in the treatment of osteoarthritis in dogs. J Am Vet Med Assoc 1995;206:807-811.
51. Welsh EM, Nolan AM, Reid J. Benefical effects of administering carprofen before surgery in dogs. Vet Rec 1997;141:251-253.
52. Lascelles BD, Butterworth SJ, Waterman AE. Postoperative analgesic and sedative effects of carprofen and pethidine in dogs. Vet Rec 1994;134:187-191.
53. Nolan A, Reid J. Comparison of the postoperative analgesic and sedative effects of carprofen and papaveretum in the dog. Vet Rec 1993;133:240-242.
54. Grisneaux E, Pibarot P, Dupuis J, Blais D. Comparison of ketoprofen and carprofen administered prior to orthopedic surgery for control of postoperative pain in dogs. J Am Vet Med Assoc 1999;215:1105-1110.
55. Ko JCH, Miyabiyashi T, Mandsager RE, Heaton-Jones TG, Mauragis DF. Renal effects of carprofen administered to healthy dogs anesthetized with propofol and isoflurane. J Am Vet Med Assoc 2000;217:346-349.
56. Priymenko N, Garnier F, Ferre JP, Delatour P, Toutain P. Enantioselectivity of the enterohepatic recycling of carprofen in the dog. Drug Metabol Disp 1998;26:170-176.
57. McKellar QA, Delatour P, Lees P. Stereospecific pharmacodynamics and pharmacokinetics of carprofen in the dog. J Vet Pharmacol Ther 1994;17:447-454.
58. Buritova J, Besson JM. Peripheral and/or central effects of racemic-, S(+)- and R(–)-flurbiprofen on inflammatory nociceptive processes: a c-Fos protein study in the rat spinal cord. Br J Pharmacol 1998;125:87-101.
59. Benton HP, Vasseur PB, Broderick-Villa GA, Koople M. Effects of carprofen on sulfated glycosaminoglycan metabolism, protein synthesis, and prostaglandin release by cultured osteoarthritic canine chondrocytes. Am J Vet Res 1997;58:286-292.
60. Reimer ME, Johnston SA, Leib MS, Duncan RB, Reimer DC, Marini M, Gimbert K. The gastroduodenal effects of buffered aspirin, carprofen, and etodolac in healthy dogs. J Vet Intern Med 1999;13:472-477.
61. McKellar QA, Pearson T, Bogan JA, Galbraith EA, Lees P, Ludwig B, Tiberghien MP. Pharmacokinetics, tolerance and serum thromboxane inhibition of carprofen in the dog. J Small Anim Pract 1990;31:443-448.
62. Mama K. New options for managing chronic pain in small animals. Vet Med 1999;94:352-356.
63. Sumano LH, De Vizcaya A, Brumbaugh GW. Tolerance and clinical evaluation of piroxicam in dogs. Canine Pract 1996;21:16-19.
64. MacPhail CM, Lappin MR, Meyer DJ, Smith SG, Webster CR, Armstrong PJ. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998;212:1895-1901.
65. Toutain PL, Cester CC, Haak T, Metge S. Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. J Vet Pharmacol Ther 2001;24:35-42.
66. Paulson SK, Kaprak TA, Gresk CJ, Fast DM, Baratta MT, Burton EG, et al. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human. Biopharm Drug Dispos 1999;20:293-299.
67. Findlay JW, Berge MA, Markos CS, Breau AP, Hribar JD, Yuan J. Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, Cynomolgus monkey and Rhesus monkey. Xenobiotica 2000;30:731-744.
68. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther 2001;297:638-645.
69. Daun JM, Ball RW, Burger HR, Cannon JG. Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo. J Leukoc Biol 1999;65:863-866.
70. Peruzzi L, Gianoglio B, Porcellini G, Conti G, Amore A, Coppo R. Neonatal chronic kidney failure associated to cyclo-oxygenase inhibitors administered during pregnancy. Minerva Urol Nefrol 2001;53:113-116.
71. Peruzzi L, Gianoglio B, Porcellini MG, Coppo R. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic. Lancet 1997;350:265-266.
72. Landau D, Shelef I, Polacheck H, Marks K, Holcberg G. Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use. Am J Perinatol 1999;16:441-444.
73. Balasubramaniam J. Nimesulide and neonatal renal failure. Lancet 2000;355:575.
74. Figueras A, Estévez F, Laporte JR. New drugs, new adverse drug reactions, and bibliographic databases. Lancet 1999;353:1447.
75. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. J Am Med Assoc 2001;286:954-959.
76. Turull A, Queralt J. Selective cyclooxygenase-2 (COX-2) inhibitors reduce anti-Mycobacterium antibodies in adjuvant arthritic rats. Immunopharmacology 2000;46:71-77.
77. Takahashi Y, Roman C, Chemtob S, Tse MM, Lin E, Heymann MA, Clyman RI. Cyclooxygenase-2 inhibitors constrict the fetal lamb ductus arteriosus both in vitro and in vivo. Am J Physiol 2000;278:R1496-R1505.
78. Isaacs JP. Adverse effects of non-steroidal anti-inflammatory drugs in the dog and cat. Austr Vet Pract 1996;26:180-186.
79. Mathews KA. Nonsteroidal anti-inflammatory analgesics in pain management in dogs and cats. Can Vet J 1996;37:539-543.
80. Vane J. Foreword. Drugs 1994;47(Suppl 5):S-P.
81. Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 1999;96:3275-3280.
Texto completo
Cómo citar este artículo
Artículos similares